Multiple Myeloma and Other Plasma Cell Disorders: Learning Objectives
Medical Importance
Plasma cell abnormalities are a heterogeneous group of diseases characterized by production of monoclonal immunoglobulin molecules. The clinical course of patients with this group of disorders ranges from indolent to life threatening. It is critical to distinguish patients for whom long-term observation is appropriate from those who have an aggressive disease that mandates immediate therapy.Objectives
- Identify the general structure of an immunoglobulin molecule, including the light chains and heavy chains, the constant and variable regions, the Fab and Fc fragments, and the differences between the various immunoglobulin classes.
- Name the major criteria used to diagnose multiple myeloma.
- Describe at least five complications that may occur in patients with multiple myeloma.
- Describe the pathophysiology of renal failure in patients with multiple myeloma.
- Describe the pathophysiology, x-ray appearance, complications, and treatment of bone abnormalities in multiple myeloma.
- Describe indications for therapy, treatment, and prognostic indicators for patients with multiple myeloma.
- Define the diagnostic criteria, incidence, and clinical course of patients with monoclonal gammopathy of unknown significance.
- Define amyloid and indicate two proteins that can cause amyloid deposition in tissues.
- Describe the clinical features and prognosis of patients with primary amyloidosis.
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission